Recent Finacing
Recent Raise
Remedy Plan Therapeutics is a clinical-stage biopharma developing hyperbolic NAMPT inhibitors (lead RPT1G) designed to partially inhibit disease-associated NAMPT to reduce healthy-tissue toxicity, advancing into Phase 1/2 AML/MDS trials.
